Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer
Authors
Keywords
-
Journal
BMC CANCER
Volume 20, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-05-20
DOI
10.1186/s12885-020-06945-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A phase II study of modified FOLFIRINOX for chemotherapy-naïve patients with metastatic pancreatic cancer
- (2018) Masato Ozaka et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Post-progression survival following second-line chemotherapy in patients with advanced pancreatic cancer previously treated with gemcitabine: a meta-analysis
- (2018) Akiyoshi Kasuga et al. INVESTIGATIONAL NEW DRUGS
- TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial)
- (2018) Tatsuya Ioka et al. EUROPEAN JOURNAL OF CANCER
- Improvement of Treatment Outcomes for Metastatic Pancreatic Cancer: A Real-world Data Analysis
- (2018) TAKASHI SASAKI et al. IN VIVO
- Multicenter phase II trial of modified FOLFIRINOX in gemcitabine-refractory pancreatic cancer
- (2018) Moon Jae Chung et al. World Journal of Gastrointestinal Oncology
- Overall Survival Prediction and Usefulness of Second-Line Chemotherapy in Advanced Pancreatic Adenocarcinoma
- (2017) Angélique Vienot et al. JNCI-Journal of the National Cancer Institute
- Effect of FOLFIRINOX as second-line chemotherapy for metastatic pancreatic cancer after gemcitabine-based chemotherapy failure
- (2017) Noritoshi Kobayashi et al. MEDICINE
- Overall Survival Prediction and Usefulness of Second-Line Chemotherapy in Advanced Pancreatic Adenocarcinoma
- (2017) Angélique Vienot et al. JNCI-Journal of the National Cancer Institute
- Pathophysiology of Chemotherapy-Induced Peripheral Neuropathy
- (2017) Hana Starobova et al. Frontiers in Molecular Neuroscience
- FOLFOX+Nab-Paclitaxel (FOLFOX-A) for Advanced Pancreatic Cancer
- (2016) Howard Safran et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- PANCREOX: A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy
- (2016) Sharlene Gill et al. JOURNAL OF CLINICAL ONCOLOGY
- Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial
- (2016) Andrea Wang-Gillam et al. LANCET
- Second-Line Treatment in Pancreatic Cancer Patients
- (2016) Marianne Sinn et al. PANCREAS
- Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort
- (2015) Alix Portal et al. BRITISH JOURNAL OF CANCER
- Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer
- (2015) S Ohkawa et al. BRITISH JOURNAL OF CANCER
- Prognostic Factors of Survival in a Randomized Phase III Trial (MPACT) of Weekly nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone in Patients With Metastatic Pancreatic Cancer
- (2015) J. Tabernero et al. ONCOLOGIST
- Retrospective analysis of fixed dose rate infusion of gemcitabine and S-1 combination therapy (FGS) as salvage chemotherapy in patients with gemcitabine-refractory advanced pancreatic cancer: inflammation-based prognostic score predicts survival
- (2014) Akiyoshi Kasuga et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase II study of FOLFIRINOX for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer
- (2014) Takuji Okusaka et al. CANCER SCIENCE
- Second-Line Oxaliplatin, Folinic Acid, and Fluorouracil Versus Folinic Acid and Fluorouracil Alone for Gemcitabine-Refractory Pancreatic Cancer: Outcomes From the CONKO-003 Trial
- (2014) Helmut Oettle et al. JOURNAL OF CLINICAL ONCOLOGY
- Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer
- (2013) M Stotz et al. BRITISH JOURNAL OF CANCER
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study
- (2011) M J Proctor et al. BRITISH JOURNAL OF CANCER
- Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: A phase III-study from the German CONKO-study group
- (2011) Uwe Pelzer et al. EUROPEAN JOURNAL OF CANCER
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More